Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence?{star, open}

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 4 SPEC. ISS., 2006, Pages 294-306

  Meinbach, David S ^a   Lokeshwar, Bal L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Growth control; Insulin like growth factor binding proteins; Insulin like growth factor 1; Metastasis; Prostate cancer; Review; Therapy

Indexed keywords

AG 538; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DEXAMETHASONE; EMI 164; ESTRAMUSTINE; ETOPOSIDE; GLUCOCORTICOID; INSULIN; MONOCLONAL ANTIBODY; OCTREOTIDE; RECEPTOR ANTIBODY; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C ANTIBODY; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANITBODY; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VITAMIN D; ZINC;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE; UPREGULATION; ZINC DEFICIENCY;

EID: 33745490771     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.12.004     Document Type: Article

References (175)

1. Bol D.K., Kiguchi K., Gimenez-Conti I., et al. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene 14 (1997) 1725-1734
2. Chan J.M., Stampfer M.K., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk. A prospective study. Science 279 (1998) 563-566
3. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins. Biologic actions. Endocr Rev 16 (1995) 3-34
4. Rinderknecht E., and Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253 (1978) 2769-2776
5. Rinderknecht E., and Humbel R.E. Primary structure of human insulin-like growth factor II. FEBS Lett 89 (1978) 283-286
6. Herington A.C., Cornell H.J., and Kuffer A.D. Recent advances in the biochemistry and physiology of the insulin-like growth factor/somatomedin family. Int J Biochem 15 (1983) 1201-1210
7. Schwander J.C., Hauri C., Zapf J., et al. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver. Dependence on growth hormone status. Endocrinology 113 (1983) 297-305
8. Tannenbaum G.S., Gudya H.J., and Posner B.I. Insulin-like growth factors. A role in growth hormone negative feedback and body weight regulation via brain. Science 220 (1983) 77-79
9. Powell-Braxton L., Hollingshead P., Warburton C., et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 7 (1993) 2609-2617
10. Sara V.R., and Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 70 (1990) 591-614
11. Damon S.E., Haugk K.L., Birnbaum R.S., et al. Retrovirally mediated overexpression of insulin-like growth factor binding protein 4. Evidence that insulin-like growth factor is required for skeletal muscle differentiation. J Cell Physiol 175 (1998) 109-120
12. Coleman M.E., DeMayo F., Yin K.C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270 (1995) 12109-12116
13. Brunetti A., Maddux B.A., Wong K.Y., et al. Muscle cell differentiation is associated with increased insulin receptor biosynthesis and messenger RNA levels. J Clin Invest 83 (1989) 192-198
14. Lindahl A., Isgaard J., Carlsson L., et al. Differential effects of growth hormone and insulin-like growth factor I on colony formation of epiphyseal chondrocytes in suspension culture in rats of different ages. Endocrinology 121 (1987) 1061-1069
15. Kulik G., and Weber M.J. Akt-dependent and independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 11 (1998) 66711-66718
16. Rosmond R., and Bjorntorp P. The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Int J Obes Relat Metab Disord 22 (1998) 1184-1196
17. Brinkman A., Groffen C., Kortleve D.J., et al. Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1). EMBO J 7 (1988) 2417-2423
18. Forbes B., Ballard F.J., and Wallace J.C. An insulin-like growth factor-binding protein purified from medium conditioned by a human lung fibroblast cell line (He[39]L) has a novel N-terminal sequence. J Endocrinol 126 (1990) 497-506
19. Brown A.L., and Rechler M.M. Cloning of the rat insulin-like growth factor-binding protein-2 gene and identification of a functional promoter lacking a TATA box. Mol Endocrinol 4 (1990) 2039-2051
20. Conover C.A., and Powell D.R. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 129 (1991) 710-716
21. Ooi G.T. Insulin-like growth factor-binding proteins (IGFBPs). More than just 1, 2, 3. Mol Cell Endocrinol 71 (1990) C39-C43
22. Clark R.G. Recombinant human insulin-like growth factor I (IGF-I). Risks and benefits of normalizing blood IGF-I concentrations. Horm Res 1 Suppl 62 (2004) 93-100
23. Juul A., Bang P., Hertel N., et al. Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults. Relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocr Metab 78 (1994) 744-752
24. O'Dell S.D., and Day I.N. Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 30 (1998) 767-771
25. Baker J., Liu J.P., Robertson E.J., et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 (1993) 73-82
26. Pavelic K., Bukovic D., and Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 8 (2002) 771-780
27. Ricort J.M. Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm IGF Res 14 (2004) 277-286
28. Baxter R.C., and Saunders H. Radioimmunoassay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 134 (1992) 133-139
29. Duan C., and Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol 142 (2005) 44-52
30. Boisclair Y.R., Rhoads R.P., Ueki I., et al. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex. An important but forgotten component of the circulating IGF system. J Endocrinol 170 (2001) 63-70
31. Baxter R.C. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrin Metab 677 (1988) 265-272
32. Arany E., Afford S., Strain A.J., et al. Differential cellular synthesis of insulin-like growth factor binding protein I and IGFBP-3 within human liver. J Clin Endocrinol Metab 79 (1994) 1871-1876
33. Rajaram S., Baylink D.J., and Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids. regulation and functions. Endocr Rev 18 (1997) 801-831
34. Schneider M.R., Lahm H., Wu M., et al. Transgenic mouse models for studying the functions of insulin-like growth factor binding proteins. FASEB J 14 (2000) 629-640
35. Guler H.P., Zapf J., Schmid C., et al. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 121 (1989) 753-758
36. Pollack M., Beamer W., and Zhang J.-C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17 (1999) 383-390
37. Moschos S.J., and Mantzoros C.S. The role of the IGF system in cancer. From basic to clinical studies and clinical applications. Oncology 63 (2002) 317-332
38. Rajah R., Kharae A., Lee P.D., et al. Insulin-like growth factor binding protein-3 is partially responsible fro high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163 (1999) 487-494
39. Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells. Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140 (1999) 1319-1328
40. Jaques G., Noll K., Wegmann B., et al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 138 (1997) 1767-1770
41. Valentinis B., Bhala A., DeAngelis T., et al. The insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9 (1995) 361-367
42. Lalou C., Lassarre C., and Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137 (1996) 3206-3212
43. Zadeh S.M., and Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type I IGF receptor gene. Endocrinology 138 (1997) 3069-3072
44. Weinzimer S.A., Gibson T.B., Collett-Solberg P.F., et al. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86 (2001) 1806-1813
45. Yang Y.W.-H., Yanagishita M., and Rechler M.M. Heparin inhibition of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human fibroblasts and rat glioma cells. Role of heparin sulfate proteoglycans. Endocrinology 137 (1996) 4363-4371
46. Liu B., Weinzimer S.A., Gibson T.B., et al. Type I alpha collagen is an IGFBP-3 binding protein. Growth Horm IGF Res 13 (2003) 89-97
47. Katz L.E.L., Rosenfeld R.G., and Cohen P. Clinical significance of insulin-like growth factor binding proteins (IGFBPs). Endocrinologist 5 (1995) 36-43
48. Mohan S., Farley J.R., and Baylink D.J. Age related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone. Implications for bone loss with aging. Prog Growth Factor Res 6 (1995) 465-473
49. Oh Y. IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer growth. Endocrine 7 (1997) 115-117
50. Ferry Jr. R.J., Katz L.E., Grimberg A., et al. Cellular actions of insulin-like growth factor-binding proteins. Horm Metab Res 31 (1999) 192-202
51. Garofalo R.S., and Rosen O.M. Insulin and insulin-like growth factor-I receptors during central nervous system development. expression of two immunologically distinct IGF-1receptor beta subunits. Mol Cell Biol 9 (1989) 2806-2817
52. LeRoith D., Werner H., Beitner-Johnson D., et al. Molecular and cellular aspects of the IGF-I receptor. Endocr Rev 16 (1995) 143-153
53. Alberola-Ila J., and Hernandez-Hoyos G. The Ras/MAPK cascade and the control of positive selection. Immun Rev 191 (2003) 79-96
54. Vincent A.M., and Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 12 (2002) 193-197
55. Rozengurt E. Convergent signaling in the action of integrin, neuropeptides, growth factors, and oncogenes. Cancer Surv 24 (1995) 81-96
56. Baserga R., Peruzzi F., and Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 107 (2003) 873-877
57. Petley T., Graff K., Jiang W., et al. Variations among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 31 (1999) 70-76
58. Alberola-Ila J., Hogquist K.A., Swan K.A., et al. Positive and negative selection invokes distinct signaling pathways. J Exp Med 184 (1996) 1-6
59. Kiely P.A., Sant A., and O'Connor R. RACK1 is an insulin-like growth factor I receptor protects tumor cells from cell death. J Biol Chem 277 (2002) 22581-22589
60. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 19 (2005) 59-71
61. Butler A.A., Blakesley V.A., Poulaki V., et al. Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 58 (1998) 3021-3027
62. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 253 (1999) 1-6
63. Nolan C.M., Kyle J.W., Watanabe H., et al. Binding of insulin-like growth factor II (IGF-II) by human cation-independent mannose 6-phosphate receptor/IGF-II receptor expressed in receptor-deficient mouse L cells. Cell Regul 1 (1990) 197-213
64. Kimura G., Kasuya J., Giannini S., et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines. LNCaP, DU145, and PC-3 cells. Int J Urol 3 (1996) 39-46
65. Guo N., Ye J.J., Liang S.J., et al. The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models. Growth Horm IGF Res 13 (2003) 44-53
66. Lowe Jr. W.L., Adamo M., Werner H., et al. Regulation of insulin-like growth factor I gene expression and binding. J Clin Invest 84 (1989) 619-626
67. Thissen J.P., Ketelslegers J.M., and Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr Rev 15 (1994) 80-101
68. Straus D.S., and Takemoto C.D. Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver. Mol Endocrinol 4 (1990) 91-100
69. Kaklamani V.G., Linos A., Kaklamani E., et al. Dietary fat and expression of the rat insulin-like growth factor I gene. J Biol Chem 262 (1987) 7894-7900
70. Kaklamani V.G., Linos A., Kaklamani E., et al. Age, sex, and smoking are predictors of circulating insulin-like growth factor I and insulin-like growth factor-binding protein 3. J Clin Oncol 17 (1999) 813-817
71. Mathews L.S., Norstedt G., and Palmiter R.D. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci USA 83 (1986) 9343-9347
72. Vincent T.S., Wulfert E., and Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophys Res Commun 180 (1991) 1284-1289
73. Ninh N.X., Thissen J.P., Maiter D., et al. Reduced liver insulin-like growth factor-I gene expression in young zinc-deprived rats is associated with a decrease in liver growth hormone (GH) receptors and serum GH-binding protein. J Endocrinol 144 (1995) 449-456
74. Matsui T., and Yamaguchi M. Zinc modulation of insulin-like growth factor's effect in osteoblastic MC3T3-E1 cells. Peptides 16 (1995) 1063-1068
75. McNall A.D., Etherton T.D., and Fosmire G.J. The impaired growth induced by zinc deficiency in rats is associated with decreased expression of the hepatic insulin-like growth factor I and growth hormone receptor genes. J Nutr 125 (1995) 874-879
76. Fielder P.J., Rosenfeld R.G., Graves H.C., et al. Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul 4 (1994) 164-172
77. Damon S.E., Plymate S.R., Carroll J.M., et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142 (2001) 21-27
78. Roberts Jr. C.T. Control of insulin-like growth factor (IGF) action by regulation of IGF-I receptor expression. Endocr J 43 Suppl (1996) S49-S55
79. Resnicoff M., Abraham D., Yutanawioonchai W., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55 (1995) 2463-2469
80. Burgaud J.L., and Baserga R. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res 223 (1996) 412-419
81. Nemoto E., Shimonishi M., Nitta Y., et al. The involvement of platelet-derived growth factor receptors and insulin-like growth factor-I receptors signaling during mineralized nodule formation by human periodontal ligament cells. J Periodontal Res 39 (2004) 388-397
82. Dickson R.B., and Lippman M.E. Estrogenic regulation of growth and polypeptide growth factor secretion inhuman breast carcinoma. Endocr Rev 8 (1987) 29-43
83. Reiter E., Bonnet P., Sente B., et al. Growth hormone and prolactin stimulate androgen receptor, insulin-like growth factor-I (IGF-I) and IGF-I receptor levels in the prostate of immature rats. Mol Cell Endocrinol 88 (1992) 77-87
84. Pepene C.E., Kasperk C.H., Pfeilschifter J., et al. Effects of triiodothyronine on the insulin-like growth factor system in primary human osteoblastic cells in vitro. Bone 29 (2001) 540-546
85. Spicer L.J., Alpizar E., and Vernon R.K. Insulin-like growth factor-I receptors in ovarian granulosa cells. effect of follicle size and hormones. Mol Cell Endocrinol 102 (1994) 69-76
86. Girnita L., Girnita A., and Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A 100 (2003) 8247-8252
87. Adams T.E., Epa V.C., Garrett T.P., et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57 (2000) 1050-1093
88. Chi M.M., Schlein A.L., and Moley K.H. High insulin-like growth factor 1 (IGF-1) and insulin concentrations trigger apoptosis in the mouse blastocyst via down-regulation of the IGF-1 receptor. Endocrinology 141 (2000) 4784-4792
89. Lin T., Wang D., Nagpal M.L., et al. Expression and regulation of insulin-like growth factor-binding protein-1, -2, -3, and -4 messenger ribonucleic acids in purified rat Leydig cells and their biological effects. Endocrinology 132 (1993) 1898-1904
90. Katz L.E., Satin-Smith M.S., Collett-Solberg P., et al. Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting. J Clin Endocrinol Metab 83 (1998) 4426-4430
91. Zapf J., Schmid C., Guler H.P., et al. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. J Clin Invest 86 (1990) 952-961
92. Camacho-Hubner C., Clemmons D.R., and D'Ercole A.J. Regulation of insulin-like growth factor (IGF) binding proteins in transgenic mice with altered expression of growth hormone and IGF-I. Endocrinology 129 (1991) 1201-1206
93. Price W.A. Regulation of insulin-like growth factor (IGF) binding protein expression of growth hormone and IGF-mediated proliferation of postnatal lung fibroblasts. Exp Lung Res 30 (2004) 261-283
94. Picardi A., Gentilucci U.V., Zardi E.M., et al. TNF-alpha and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res 23 (2003) 229-235
95. Phillips L.S., Pao C.I., and Villafuerte B.C. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 60 (1998) 195-265
96. Krishnan A.V., Peehl D.M., and Feldman D. Inhibition of prostate cancer growth by vitamin D. Regulation of target gene expression. J Cell Biochem 88 (2003) 363-371
97. Bertherat J. Insulin-like growth factor binding protein 3 (IGFBP-3). A novel target of the tumor suppressor p53 inhibiting cell growth. Eur J Endocrinol 134 (1996) 426-427
98. Neuberg M., Buckbinder L., Seizinger B., et al. The p53/IGF-1 receptor axis in the regulation of programmed cell death. Endocrine 7 (1997) 107-109
99. Grimberg A. P53 and IGFBP-3. Apoptosis and cancer protection. Mol Genet Metab 70 (2000) 85-98
100. Cohen P., Graves C.B., Peehl D.M., et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75 (1992) 1046-1053
101. Ferry Jr. R.J., Katz L.E., Grimberg A., et al. Cellular actions of insulin-like growth factor-binding proteins. Horm Metab Res 31 (1999) 192-202
102. Lee K.O., Oh Y., Giudice L.C., et al. Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma. A comparison of normal and vasectomized patients. J Clin Endocrinol Metab 79 (1994) 1367-1372
103. Rehault S., Monget P., Mazerbourg S., et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268 (2001) 2960-2968
104. Rajah R., Katz L., Nunn S., et al. Insulin-like growth factor binding protein proteases. Functional regulators of cell growth. Prog Growth Factor Res 6 (1996) 273-284
105. Angelloz-Nicoud P., and Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136 (1995) 5485-5492
106. Conover C., and DeLeon D.D. Acid activated insulin-like growth factor binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin-D. J Biol Chem 80 (1994) 987-993
107. Zheng B., Clarke J.B., Busby W.H., et al. Insulin-like growth factor binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology 139 (1998) 1708-1714
108. Cohen S.M. Role of cell proliferation in multistage carcinogenesis. Proc Soc Exp Biol Med 198 (1991) 683-687
109. Preston-Martin S., Pike M.C., Ross R.K., et al. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 101 (1993) 137-138
110. DiGiovanni J., Kiguchi K., Frijhoff, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 97 (2000) 3455-3460
111. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol 3 (2002) 298-302
112. Grothey A., Voigt W., Schober C., et al. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 125 (1999) 166-173
113. Tricoli J.V., Winter D.L., Hanlon A.L., et al. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54 (1999) 178-182
114. Mantzoros C.S., Tzonou A., Signorello L.B., et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76 (1997) 1115-1118
115. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk-Interpreting the evidence. J Natl Cancer Inst 90 (1998) 876-879
116. Chen C., Lewis S.K., Voigt L., et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103 (2005) 76-84
117. Kaicer E.K., Blat C., and Harel L. IGF-I and IGF-binding proteins. Stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4 (1991) 231-237
118. Pietrzkowski Z., Mulholland G., Gomella L., et al. Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor-1. Cancer Res 53 (1993) 1102-1106
119. Iwamura M., Sluss P.M., Casamento J.B., et al. Insulin-like growth factor I. Action and receptor characterization in human prostate cancer cell lines. Prostate 22 (1993) 243-252
120. Kaplan P.J., Subburaman M., and Cohen P. The insulin-like growth factor axis and prostate cancer. Lessons from the transgenic adenocarcinoma of mouse prostate (Tramp) model. Cancer Res 59 (1999) 2203-2209
121. Dews M., Nishimoto I., and Baserga R. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Recept Signal Transduc 7 (1997) 231-240
122. Miyake H., Nelson C., Rennie P.S., et al. Over expression of insulin-like growth factor binding protein-5 help accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141 (2000) 2257-2265
123. Nickerson T., Chang F., Lorimer D., et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61 (2001) 6276-6280
124. Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94 (2002) 1099-1106
125. Kanety B.H., Madjar Y., Dagan Y., et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer. Correlation with serum prostate specific antigen. J Clin Endocrinol Metab 77 (1993) 229-233
126. Nickerson T., Pollak M., and Huynh H. Castration induced apoptosis in rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding protein 2,3,4 and 5. Endocrinology 139 (1998) 807-810
127. Rajah R., Khare A., Lee P.D., et al. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163 (1999) 487-494
128. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13 (2003) 113-170
129. Li L., Yu H., Schumacher F., et al. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14 (2003) 721-726
130. Mutaguchi K., Yasumoto H., Mita K., et al. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63 (2003) 7717-7723
131. Komatsu S., Okazaki Y., Tateno M., et al. Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun 267 (2000) 109-117
132. Mutaguchi K., Yasumoto H., Mita K., et al. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63 (2003) 7717-7723
133. Drivdahl R.H., Loop S.M., Andress D.L., et al. IGF-binding proteins in human prostate tumor cells. Expression and regulation by 1,25,-dihydroxy Vitamin D3. Prostate 26 (1995) 72-79
134. Willden E.G., and Robinson M.R. Plasma zinc levels in prostatic disease. Br J Urol 47 (1975) 295-299
135. Costello L.C., and Franklin B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 35 (1998) 285-296
136. Yaman M., Atici D., Bakirdere S., et al. Comparison of trace metal concentrations in malign and benign human prostate. J Med Chem 48 (2005) 630-634
137. Malm J., Hellman J., Hogg P., et al. Enzymatic action of prostate-specific antigen (PSA or hK3). Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 45 (2000) 132-139
138. de Launoit Y., Veilleux R., Dufour M., et al. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51 (1991) 5165-5170
139. Smith G.L., Doherty A.P., Mitchell H., et al. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer. Lancet 354 (1999) 2053-2054
140. Koistinen H., Paju A., Koistinen R., et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50 (2002) 112-118
141. Huynh H., Seyam R.M., and Brock G.B. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 58 (1998) 215-218
142. Orio Jr. F., Terouanne B., Georget V., et al. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and trans-activation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198 (2002) 105-114
143. Culig Z., Hobisch A., Cronauer M.V., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
144. Wolk A., Mantzoros C.S., Andersson S.-O., et al. Insulin-like growth factor I and prostate cancer risk. A population-based, case-control study. J Natl Cancer Inst 90 (1998) 911-915
145. Aksoy Y., Aksoy H., Bakan E., et al. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 72 (2004) 62-65
146. Plymate S.R., Bae V.L., Maddison L., et al. Re-expression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138 (1997) 1728-1735
147. Bahr G., and Groner B. The IGF-1 receptor and its contribution to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 23 (2005) 1-14
148. Mauro L., Salerno M., Morelli C., et al. Role of the IGF-I receptor in the regulation of cell-cell adhesion. Implications in cancer development and progression. J Cell Physiol 194 (2003) 108-116
149. Pollak M., Beamer W., and Zhang J.C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17 (1999) 383-390
150. Djavan B., Waldert M., Seitz C., et al. Insulin-like growth factors and prostate cancer. World J Urol 19 (2001) 225-233
151. Shariat S.F., Bergamaschi F., Adler H.L., et al. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology 56 (2000) 423-429
152. Lopez J.B., Sahabudin R.M., and Chin L.P. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?. Int J Biol Markers 19 (2004) 164-167
153. Ismail H.A., Pollak M., Behlouli H., et al. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int 92 (2003) 699-702
154. Tennant M.K., Thrasher J.B., Twomey P.A., et al. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81 (1996) 3774-3782
155. Tennant M.K., Thrasher J.B., Twomey P.A., et al. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 81 (1996) 411-420
156. Rubin J., Chung L.W., Fan X., et al. Prostate carcinoma cells that have resided in bone have an up regulated IGF-I axis. Prostate 58 (2004) 41-49
157. Kaplan P.J., Mohan S., Cohen P., et al. The insulin-like growth factor axis and prostate cancer. Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59 (1999) 2203-2209
158. Nickerson T., Miyake H., Gleave M.E., et al. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 59 (1999) 3392-3395
159. Moore M.G., Wetterau L.A., Francis M.J., et al. Novel stimulatory role for insulin-like growth factor-binding proteins. Int J Cancer 105 (2003) 14-19
160. Kiyama S., Morrison K., Zellweger T., et al. Castration-induced increases in insulin-like growth factor binding protein-2 in prostate LNCaP tumors. Cancer Res 63 (2003) 3575-3584
161. Surmacz E. Growth factor receptors as therapeutic targets. Strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22 (2003) 6589-6597
162. Letsch M., Schally A.V., Nagy A., et al. Effective treatment of experimental DU-145 prostate cancer with targeted cytotoxic somatostatin analog AN-238. Int J Oncol 20 (2002) 397-402
163. Letsch M., Schally A.V., Szepeshazi K., et al. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol 171 (2003) 911-915
164. Vainas I.G. Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 47 Suppl 2 (2001) 109-126
165. Arteaga C.L., Kitten L.J., Coronado E.B., et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84 (1989) 1418-1423
166. Jacobs S., Cook S., Svoboda M.E., et al. Interaction of the monoclonal antibodies alpha IR-1 and alpha IR-3 with insulin and somatomedin-C receptors. Endocrinology 118 (1986) 223-226
167. Kimura G., Kasuya J., Giannini S., et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines. LNCaP, DU145, and PC-3 cells. Int J Urol 3 (1996) 39-46
168. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 (2003) 5073-5083
169. Pietrzkowski Z., Mulholland G., Gomella L., et al. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53 (1993) 1102-1106
170. Blum G., Gazit A., and Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278 (2003) 40442-40454
171. Hamy F., Brondani V., Spoerri R., et al. Specific block of androgen receptor activity by antisense oligonucleotides. Prostate Cancer Prostatic Dis 6 (2003) 27-33
172. Gleave M., Nelson C., and Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 4 (2003) 209-221
173. O'Byrne K.J., Dobbs N., Propper D.J., et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 79 (1999) 1413-1418
174. Gonzalez-Barcena D., Schally A.V., Vadillo-Buenfil M., et al. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 56 (2003) 183-191
175. Dimopoulos M.A., Kiamouris C., Gika D., et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer. A randomized phase II study. Urology 63 (2004) 120-125